VivoSeq
Other

High Risk

1

Pipeline Programs↗

18

Active Trials↗

4

Companies Involved↗

High Risk is an early-stage landscape with 1 program across 4 companies. The most active players are Novartis, Bristol-Myers Squibb, Waymark.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

30/100

Mech. Concentration

N/A

Completion Rate

66/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalW

Waymark

0 programs

PreclinicalI

Idoven 1903 S.L.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Fludarabine and Cyclophosphamide

Beijing Immunochina Medical Science & Technology Co., Ltd.

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

60

clinical trials

Completed23 · 38%
Terminated10 · 17%
Unknown status7 · 12%
Recruiting7 · 12%
Active, not recruiting6 · 10%
Not yet recruiting5 · 8%
Other2 · 3%

Clinical Trials

Trial Activity

60 trials

Do Penicillin-allergic Patients Presents a High Risk of Sinus Lift Failure
Recruiting·UUniversitat Internacional de Catalunya·N/A·NCT06504888·400 enrolled
Early Intervention in High Risk CCUS
Recruiting·—·Phase 1·NCT06802146·108 enrolled
High Dose Oral Omeprazole in High Risk UGIB
Recruiting·KKing Chulalongkorn Memorial Hospital·N/A·NCT04394663·128 enrolled
PSMA PET Response Guided SabR in High Risk Pca
Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT06044857·20 enrolled
Clinical Study on the Safety and Efficacy of CAR BCMA-CD70 Dual-target CAR-T Therapy for High-risk Plasma Cell Neoplasms
Recruiting·AAffiliated Hospital to Academy of Military Medical Sciences·Phase 1·NCT07416682·20 enrolled
Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG Platform
Recruiting·IIdoven 1903 S.L.·N/A·NCT07333547·200,000 enrolled
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT05013216·37 enrolled
Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients
Active, not recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 2·NCT04097470·140 enrolled
Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers
Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT03347838·19 enrolled
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
Active, not recruiting·FFudan University·Phase 2/3·NCT02641847·503 enrolled
Hepatoprotective Measures for Children at High Risk of NAFLD
Active, not recruiting·—·Phase 4·NCT06918080·200 enrolled
A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR
Active, not recruiting·—·Phase 2/3·NCT05660447·80 enrolled
Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05015426·20 enrolled
Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal Haematopoiesis
Not yet recruiting·CClinical Hub for Interventional Research (CHOIR)·Phase 2·NCT07435636·80 enrolled
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07257055·30 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)